Needham Maintains Buy on Harmonic, Maintains $19 Price Target

Needham analyst Ryan Koontz maintains Harmonic (NASDAQ:HLIT) with a Buy and maintains $19 price target.

byBenzinga Newsdesk

February 17, 2023

1 minute read

Needham analyst Ryan Koontz maintains Harmonic (NASDAQ:HLIT) with a Buy and maintains $19 price target.

Exela Amends Existing Securitization Facility & Reduces 2023 Debt Maturities

By Anusuya Lahiri

Today, 3:29 AM

Exela Technologies, Inc (NASDAQ:XELA) reported that its subsidiaries had obtained $51 million of new funding from B. Riley Commercial…

XELA

Movers
News

What’s Going On With Lucid Stock Today?

By Adam Eckert

Today, 3:29 AM

Lucid Group Inc (NASDAQ: LCID) shares are up 5% Thursday afternoon after the company turned in production numbers that topped its prior forecast.

LCID

A Power Outage At JFK Terminal 1 Is Impacting The Terminal’s Ability To Accept Inbound And Outbound Flights. We Are Working To Accommodate Impacted Flights Using Other Terminals

By Happy Mohamed

Today, 3:29 AM

John F Kennedy Airport's Terminal 1 serves Aeroflot, Aero Mexico, Air China, Air France, AirPlus Comet, Alitalia, Austrian Airlines, Cayman Airways, China Airlines, China Eastern, Japan Airlines, Korean Air,

SPY

Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

By Benzinga Insights

Today, 3:29 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $77.02 billion.

REGN

Needham Maintains Buy on Harmonic, Maintains $19 Price Target

Related Posts

Exela Amends Existing Securitization Facility & Reduces 2023 Debt Maturities

What’s Going On With Lucid Stock Today?

A Power Outage At JFK Terminal 1 Is Impacting The Terminal’s Ability To Accept Inbound And Outbound Flights. We Are Working To Accommodate Impacted Flights Using Other Terminals

Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years